NASD · Healthcare · Biotechnology · USA
Bicara Therapeutics Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program, ficerafusp alfa, combines an EGFR-directed antibody with a TGF-β ligand trap designed to enhance tumor penetration and limit systemic toxicity. The company is evaluating ficerafusp alfa in combination with pembrolizumab for head and neck squamous cell carcinoma in its pivotal trial.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Bicara Therapeutics Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
134 more in this industry show a wider margin of safety.
We do not publish a verdict on BCAX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-30 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.